🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Zhi-Gan Formula improved insomnia and anxiety comorbidity in a mouse model via PACAP signaling in the medial prefrontal cortex.

PMID: 41525914 · DOI: 10.1016/j.jep.2026.121185 · Journal of ethnopharmacology, 2026 · Ruiyi Liu, Zhangjie Wu, Ying Yin, Chenghao Song, Chengyu Zhang, Shan Xing, Jingwen Tan, Zhenzhen Fu, Nga Lee Wong, Mingx
📄 Abstract

Insomnia and anxiety are highly comorbid, severely compromising quality of life. Efficacy of current pharmacological interventions for this dual condition remains limited. Zhi-Gan Formula (ZG), consisting of Zhi-Zi-Chi Decoction and Ganmai Dazao Decoction, two classic Traditional Chinese Medicine (TCM) formulae clinically widely used for insomnia or anxiety, holds promise as a therapeutic option for insomnia-anxiety comorbidity. This study aimed to assess ZG's sleep-promoting and anxiolytic efficacy, and investigate the novel mechanism through which pituitary adenylate cyclase-activating polypeptide (PACAP) in the medial prefrontal cortex (mPFC) modulates comorbid sleep and anxiety conditions. Mice received 4-chloro-DL-phenylalanine (PCPA) injections and were subsequently administered ZG or diazepam. Behaviors were assessed using the pentobarbital-induced sleep test, open-field test (OFT), and elevated plus-maze test (EPM). Key pathways were identified via network pharmacology analysis and validated using long-term potentiation (LTP) recordings and protein quantification. Viral-mediated PACAP knockdown vectors were transfected into the mPFC. PCPA administration induced insomnia and anxiety-like behaviors. ZG administered for 3 days significantly shortened sleep latency, prolonged sleep duration, and alleviated anxiety-like behaviors, whereas diazepam only partially improved anxiety-like behaviors. Network pharmacology analysis suggested ZG's engagement in neuropeptide-receptor interactions and synaptic transmission pathways. Assessments of synaptic plasticity showed that ZG improved mPFC LTP and the expression of synaptic proteins (PSD95, synapsin-1, BDNF) impaired in the model mice. Moreover, the expression of the neuropeptide PACAP and downstream eEF2 signaling for synaptic protein synthesis were all improved by ZG. Crucially, perfusion of a PACAP agonist in the mPFC brain slices from sleep-deprived mice rescued LTP deficits. Finally, mPFC PACAP knockdown abolished the therapeutic effects and the enhanced expressions of the synaptic proteins by ZG. ZG alleviated insomnia-anxiety comorbidity by restoring synaptic plasticity in the mPFC via the PACAP-eEF2-BDNF pathway, which may also shed light on the development of a novel therapeutic approach for the treatment of sleep-anxiety comorbidity.

Confidence: 0.23 · 11 полей извлечено
Идентификация (6 полей)
Target
pituitary adenylate cyclase-activating polypeptide
1.00
Alt. target
PACAP
1.00
Protein family
—
0.00
Functional class
—
0.00
Subcellular loc.
—
0.00
Isoforms (metab/obesity)
—
0.00
Механизм действия (21 полей)
Mechanism
—
0.00
Mutations (obesity/lean)
—
0.00
Activity (obesity)
—
0.00
Activity temporal
—
0.00
Energy balance
—
0.00
Appetite
—
0.00
Fat metabolism
—
0.00
Lipolysis
—
0.00
Thermogenesis
—
0.00
Muscle metabolism
—
0.00
Inflammation
—
0.00
Glucose metabolism
—
0.00
AA metabolism
—
0.00
Hormonal pathways
—
0.00
Cell death
—
0.00
Adipocyte fibrosis
—
0.00
Upstream (biochem)
—
0.00
Upstream (physiol)
—
0.00
Downstream (biochem)
—
0.00
Downstream (physiol)
—
0.00
PTMs
—
0.00
Экспрессия (8 полей)
Tissue expression
PACAP, PSD95, synapsin-1, BDNF, eEF2 in medial prefrontal cortex
0.90
In vitro
mPFC brain slices from sleep-deprived mice
0.90
In vivo
PCPA-induced insomnia and anxiety mouse model; behavioral tests (pentobarbital-induced sleep test, OFT, EPM); ZG and diazepam administration; viral-mediated PACAP knockdown in mPFC
0.95
In silico
network pharmacology analysis
0.90
Genetic association
—
0.00
Ex vivo
LTP recordings in mPFC brain slices; PACAP agonist perfusion
0.90
Animal model
mouse
0.95
Diet/model
PCPA-induced insomnia and anxiety model
0.90
Клиника (11 полей)
Drug
Zhi-Gan Formula
1.00
Indication
insomnia and anxiety comorbidity
1.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00